Antinociceptive effect of Arvelexin in male mouse models.

This research evaluated the analgesic properties of Arvelexin through different models of nociception. Different concentrations of Arvelexin (50, 100, 150, and 200 µg/kg body weight) were administered to male mice, and their responses to pain were assessed using various evaluation techniques. The results were compared with those from mice receiving treatments of acetylsalicylic acid or morphine, with and without the addition of naloxone. Furthermore, to explore the impact of Arvelexin on pain modulation systems, additional tests using capsaicin and glutamate focused on its influence on vanilloid and glutamatergic pathways. The research illustrated a significant, dose-related reduction in pain during the acetic acid-induced writhing assay, with a peak decrease of 75.1% observed at 200 µg/kg body weight. Similarly, Arvelexin increased the delay before pain response in the hot plate test by 69.5% at the same dosage. In tests of formalin-induced paw licking, Arvelexin notably reduced pain in both the neurogenic and inflammatory phases, effects which were negated by naloxone, suggesting opioid system engagement. Furthermore, the compound effectively inhibited neurogenic pain triggered by capsaicin and glutamate. ELISA results showed that Arvelexin markedly reduced levels of pro-inflammatory cytokines (IL-1β, TNF-α, and IFN-γ) in the serum of mice at 100 and 200 µg/kg. The results demonstrate that Arvelexin has analgesic effects mediated by both central and peripheral pathways, involving interactions with vanilloid receptors, opioid receptors, and elements of the glutamatergic system. While findings suggest significant pain relief, the exclusion of female mice may limit the applicability of results across sexes.